Rosetta sets strategic alliance

|About: Rosetta Genomics Ltd. (ROSG)|By:, SA News Editor

Pico caps Rosetta Genomics (ROSG) and Marina Biotech (MRNA) establish a strategic collaboration to identify and develop microRNA-based products targeting neuromuscular diseases and dystrophies.

Initial focus will be Becker and Duchenne muscular dystrophies and myotonic dystrophy.

Rosetta will identify microRNAs associated with the diseases and, if correlative, will develop the diagnostic products. Marina will develop the therapeutics.